SentenceSentimentTitleUrlDate
Catalyst CEO Patrick McEnany declined to comment except to say that the company would be responding to Senator Sanders request in a timely manner NegativeNEW YORK Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease which had long been available to patients for free will cost more than per year including rebates to insurers and other discounts http://www.reuters.com/news/health/article/us-catalyst-pharms-drugpricing/catalyst-pharma-sees-net-price-of-drug-once-free-topping-300000-idUSKCN1Q02862019-02-12